Recent advances with chemotherapy for NSCLC

The ECOG experience

D. H. Johnson, Alex Y Chang, David S Ettinger, Mann Kim Kyung Mann Kim, P. Bonomi

Research output: Contribution to journalArticle

Abstract

Management of disseminated non-small-cell lung cancer has changed over the past 10 years. Newer agents, such as vinorelbine (Navelbine) and paclitaxel (Taxol), have been shown to modestly improve survival in patients with advanced disease when administered in conjunction with cisplatin (Platinol). Compared with older regimens consisting of cisplatin and a Vinca alkaloid or a podophyllotoxin, the newer regimens yield a 10- to 15-week improvement in median survival and an additional 10% to 15% in 1-year survival. Based on these results derived from randomized trials, it appears that metastatic non-small-cell lung cancer patients with gook performance status should be treated with regimens containing either vinorelbine or paclitaxel in conjunction with cisplatin.

Original languageEnglish (US)
Pages (from-to)67-70
Number of pages4
JournalOncology
Volume12
Issue number1 SUPPL. 2
StatePublished - 1998

Fingerprint

Cisplatin
Paclitaxel
Drug Therapy
Non-Small Cell Lung Carcinoma
Survival
Podophyllotoxin
Vinca Alkaloids
vinorelbine

ASJC Scopus subject areas

  • Oncology

Cite this

Johnson, D. H., Chang, A. Y., Ettinger, D. S., Kyung Mann Kim, M. K., & Bonomi, P. (1998). Recent advances with chemotherapy for NSCLC: The ECOG experience. Oncology, 12(1 SUPPL. 2), 67-70.

Recent advances with chemotherapy for NSCLC : The ECOG experience. / Johnson, D. H.; Chang, Alex Y; Ettinger, David S; Kyung Mann Kim, Mann Kim; Bonomi, P.

In: Oncology, Vol. 12, No. 1 SUPPL. 2, 1998, p. 67-70.

Research output: Contribution to journalArticle

Johnson, DH, Chang, AY, Ettinger, DS, Kyung Mann Kim, MK & Bonomi, P 1998, 'Recent advances with chemotherapy for NSCLC: The ECOG experience', Oncology, vol. 12, no. 1 SUPPL. 2, pp. 67-70.
Johnson DH, Chang AY, Ettinger DS, Kyung Mann Kim MK, Bonomi P. Recent advances with chemotherapy for NSCLC: The ECOG experience. Oncology. 1998;12(1 SUPPL. 2):67-70.
Johnson, D. H. ; Chang, Alex Y ; Ettinger, David S ; Kyung Mann Kim, Mann Kim ; Bonomi, P. / Recent advances with chemotherapy for NSCLC : The ECOG experience. In: Oncology. 1998 ; Vol. 12, No. 1 SUPPL. 2. pp. 67-70.
@article{35416f4cfe28410dab1226c0b2b904f5,
title = "Recent advances with chemotherapy for NSCLC: The ECOG experience",
abstract = "Management of disseminated non-small-cell lung cancer has changed over the past 10 years. Newer agents, such as vinorelbine (Navelbine) and paclitaxel (Taxol), have been shown to modestly improve survival in patients with advanced disease when administered in conjunction with cisplatin (Platinol). Compared with older regimens consisting of cisplatin and a Vinca alkaloid or a podophyllotoxin, the newer regimens yield a 10- to 15-week improvement in median survival and an additional 10{\%} to 15{\%} in 1-year survival. Based on these results derived from randomized trials, it appears that metastatic non-small-cell lung cancer patients with gook performance status should be treated with regimens containing either vinorelbine or paclitaxel in conjunction with cisplatin.",
author = "Johnson, {D. H.} and Chang, {Alex Y} and Ettinger, {David S} and {Kyung Mann Kim}, {Mann Kim} and P. Bonomi",
year = "1998",
language = "English (US)",
volume = "12",
pages = "67--70",
journal = "Oncology",
issn = "0890-9091",
publisher = "UBM Medica Healthcare Publications",
number = "1 SUPPL. 2",

}

TY - JOUR

T1 - Recent advances with chemotherapy for NSCLC

T2 - The ECOG experience

AU - Johnson, D. H.

AU - Chang, Alex Y

AU - Ettinger, David S

AU - Kyung Mann Kim, Mann Kim

AU - Bonomi, P.

PY - 1998

Y1 - 1998

N2 - Management of disseminated non-small-cell lung cancer has changed over the past 10 years. Newer agents, such as vinorelbine (Navelbine) and paclitaxel (Taxol), have been shown to modestly improve survival in patients with advanced disease when administered in conjunction with cisplatin (Platinol). Compared with older regimens consisting of cisplatin and a Vinca alkaloid or a podophyllotoxin, the newer regimens yield a 10- to 15-week improvement in median survival and an additional 10% to 15% in 1-year survival. Based on these results derived from randomized trials, it appears that metastatic non-small-cell lung cancer patients with gook performance status should be treated with regimens containing either vinorelbine or paclitaxel in conjunction with cisplatin.

AB - Management of disseminated non-small-cell lung cancer has changed over the past 10 years. Newer agents, such as vinorelbine (Navelbine) and paclitaxel (Taxol), have been shown to modestly improve survival in patients with advanced disease when administered in conjunction with cisplatin (Platinol). Compared with older regimens consisting of cisplatin and a Vinca alkaloid or a podophyllotoxin, the newer regimens yield a 10- to 15-week improvement in median survival and an additional 10% to 15% in 1-year survival. Based on these results derived from randomized trials, it appears that metastatic non-small-cell lung cancer patients with gook performance status should be treated with regimens containing either vinorelbine or paclitaxel in conjunction with cisplatin.

UR - http://www.scopus.com/inward/record.url?scp=0031914644&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031914644&partnerID=8YFLogxK

M3 - Article

VL - 12

SP - 67

EP - 70

JO - Oncology

JF - Oncology

SN - 0890-9091

IS - 1 SUPPL. 2

ER -